PUMA抗体;PUMA Antibody—艾普蒂 新品

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of PUMA expression in K562 cell lysate.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:50 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:150 dilution.    

  
  

•  

   

     Immunofluorescent analysis using the Antibody at 1:200 dilution.    

  
  

•  

   

     Immunofluorescent analysis of Hela cells, using PUMA Antibody .    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human breast cancer, using PUMA Antibody.    

  
  

The p53-upregulated modulator of apoptosis (PUMA) is a pro-apoptotic protein belonging to the BCL-2 family, initially identified as a key mediator of p53-dependent apoptosis. Structurally, PUMA contains a BH3 domain critical for its interaction with anti-apoptotic BCL-2 family members (e.g., BCL-2. BCL-XL). Upon cellular stress, such as DNA damage or oncogenic activation, p53 transcriptionally activates PUMA, which neutralizes anti-apoptotic proteins, leading to mitochondrial outer membrane permeabilization, cytochrome c release, and caspase activation. PUMA also operates in p53-independent pathways under conditions like growth factor deprivation or endoplasmic reticulum stress.

PUMA antibodies are essential tools for studying its expression, localization, and function in apoptosis regulation. These antibodies enable detection via techniques like Western blotting, immunohistochemistry, and flow cytometry. Researchers utilize PUMA-specific antibodies to investigate its role in diseases, particularly cancer, where PUMA dysregulation contributes to tumor progression or therapy resistance. Additionally, studies explore PUMA's involvement in neurodegenerative disorders and ischemic injuries. Validated antibodies are crucial to ensure specificity, as PUMA shares homology with other BH3-only proteins. Recent advancements in antibody development, including monoclonal and phospho-specific variants, have enhanced precision in tracking PUMA dynamics and post-translational modifications, furthering insights into apoptotic signaling networks.